New Neuromodulator Letybo Approved for U.S. Use

The FDA-cleared treatment offers a new option for adults seeking to reduce glabellar lines.

Updated on Oct. 26, 2026 in Beauty

Bold vector editorial illustration showing two minimalist empty glass medical vials on a clean surface, representing clinical cosmetic treatment. — The FDA has approved the use of Letybo in the U.S., offering a new botulinum toxin A option for reducing glabellar lines. AI Illustration. Upload story photo >

Live Poll

Is now a good time to consider cheaper alternatives to established cosmetic neuromodulator brands?

In 2024, the FDA approved the use of the neuromodulator Letybo in the United States for the treatment of glabellar lines. This botulinum toxin A-based product offers patients an additional option for temporary cosmetic improvement.

Why it matters

Letybo provides an alternative in the neuromodulator market by utilizing a formulation with fewer complexing proteins. This development expands the landscape of available treatments for those looking to address facial lines.

The FDA cleared Letybo in 2024 for the treatment of glabellar lines using botulinum toxin A. While results typically last 12 to 16 weeks, the clinical comparison of its effectiveness against other neuromodulators is still being evaluated by practitioners.

The players

FDA

The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and drugs.

Hugel

The pharmaceutical company that manufactures Letybo.

The details

Letybo functions by utilizing botulinum toxin A to block acetylcholine, which prevents the underlying muscle from contracting. It distinguishes itself by containing fewer complexing proteins compared to most existing neuromodulators on the market. Manufacturers offer the product in flexible quantities, allowing medical practices to purchase individual vials rather than meeting the high minimums required by some other brands.

2024: FDA cleared Letybo for U.S. use.
Three days: Letybo onset time for most patients.
5 to 7 days: Typical onset time for Botox.
12 to 16 weeks: Duration of Letybo treatment results.

Health Landscape

Letybo enters an established market dominated by products like Botox, representing a diversification of available neuromodulator therapies. This expansion offers practitioners more flexible purchasing options when treating patients with similar cosmetic goals.

Individuals considering treatment for glabellar lines may discuss Letybo with their provider to see if the product's profile or cost structure aligns with their needs. It is important to ask your physician about individual expected results and potential side effects before beginning any new treatment.

The takeaway

Letybo offers a new option for managing glabellar lines, with an onset time of approximately three days. When evaluating cosmetic procedures, consult your dermatologist or plastic surgeon to review which FDA-cleared neuromodulator is appropriate for your specific health history.